盟科药业-U
(688373)
| 流通市值：22.62亿 | | | 总市值：40.52亿 |
| 流通股本：3.66亿 | | | 总股本：6.56亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 33,216,965.04 | 130,272,762.01 | 97,562,309.83 | 60,738,238.45 |
| 营业收入 | 33,216,965.04 | 130,272,762.01 | 97,562,309.83 | 60,738,238.45 |
| 二、营业总成本 | 96,412,359.38 | 581,598,318.57 | 394,736,146.75 | 267,528,409.42 |
| 营业成本 | 5,138,953.41 | 22,405,200.94 | 17,337,542.92 | 11,230,464.78 |
| 税金及附加 | 286,212.87 | 407,657.11 | 89,872.24 | 66,178.35 |
| 销售费用 | 22,406,451.74 | 110,491,483.35 | 81,584,801.56 | 52,686,296.89 |
| 管理费用 | 12,922,537.3 | 66,295,410.29 | 43,878,114.42 | 31,291,313.88 |
| 研发费用 | 53,852,131.73 | 368,564,368.34 | 244,246,074.92 | 166,167,389.94 |
| 财务费用 | 1,806,072.33 | 13,434,198.54 | 7,599,740.69 | 6,086,765.58 |
| 其中:利息费用 | 3,149,649.18 | 11,152,052.44 | 9,083,372.02 | 5,017,813.52 |
| 其中:利息收入 | 849,401.23 | 2,369,037.68 | 1,876,598.02 | 1,658,578.6 |
| 加:公允价值变动收益 | 1,465,382.57 | 17,081,843.88 | 11,834,083.76 | 9,930,647.6 |
| 资产处置收益 | 49,427.63 | 27,456.31 | - | - |
| 信用减值损失(新) | -109,123.09 | -1,637,220.51 | -221,984.55 | 27,506.67 |
| 其他收益 | 158,286.61 | 1,364,746.04 | 440,637.84 | 291,127.34 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -61,631,420.62 | -434,488,730.84 | -285,121,099.87 | -196,540,889.36 |
| 加:营业外收入 | - | - | 2,546.7 | - |
| 减:营业外支出 | 1,055.07 | 22,886.13 | 16,286.13 | 5,803.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -61,632,475.69 | -434,511,616.97 | -285,134,839.3 | -196,546,693.17 |
| 减:所得税费用 | - | 6,209,600.12 | 6,161,306.69 | 4,757,553.64 |
| 六、净利润 | -61,632,475.69 | -440,721,217.09 | -291,296,145.99 | -201,304,246.81 |
| 持续经营净利润 | -61,632,475.69 | -440,721,217.09 | -291,296,145.99 | -201,304,246.81 |
| 归属于母公司股东的净利润 | -61,632,475.69 | -440,721,217.09 | -291,296,145.99 | -201,304,246.81 |
| (一)基本每股收益 | -0.09 | -0.67 | -0.44 | -0.31 |
| (二)稀释每股收益 | -0.09 | -0.67 | -0.44 | -0.31 |
| 八、其他综合收益 | -816,039.59 | 6,175,113.78 | 1,623,228.55 | 4,298,551.74 |
| 归属于母公司股东的其他综合收益 | -816,039.59 | 6,175,113.78 | 1,623,228.55 | 4,298,551.74 |
| 九、综合收益总额 | -62,448,515.28 | -434,546,103.31 | -289,672,917.44 | -197,005,695.07 |
| 归属于母公司股东的综合收益总额 | -62,448,515.28 | -434,546,103.31 | -289,672,917.44 | -197,005,695.07 |
| 公告日期 | 2025-04-24 | 2025-03-18 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |